12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Isavuconazole: Phase III

Basilea completed enrollment of 150 patients with pre-existing renal impairment or with invasive fungal disease in the open-label, international Phase III VITAL trial evaluating 200 mg IV or oral isavuconazole. The product has Fast Track designation...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >